Comparing guidelines for adjuvant endocrine therapy in postmenopausal women with breast cancer: a coming of age

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin.59, 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol.18, 581–592 (2007).
   PubMed Web of Science ®Google Scholar
• Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2008. Toronto, Canada (2008).
   Google Scholar
• Aiello EJ, Buist DS, Wagner EH et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res. Treat.107, 397–403 (2008).
   PubMed Web of Science ®Google Scholar
• Pronzato P, Cazzaniga ME, Mustacchi G et al. Factors influencing the switch from tamoxifen (TAM) to aromatase inhibitors (AIs) as adjuvant therapy in early breast cancer (EBC) patients (pts). Results from the NORA study. J. Clin. Oncol.24(18S), 578s (2006) (Abstract 10633).
   Google Scholar
• Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; panel members. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann. Oncol.20, 1319–1329 (2009).
   PubMed Web of Science ®Google Scholar
• Kataja V, Castiglione M; ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.20(Suppl. 4), 10–14 (2009).
   PubMed Web of Science ®Google Scholar
• Namer M, Gligorov J, Luporsi E, Serin D. ‘Breast cancers’ recommendations for clinical practice from Saint Paul de Vence. Oncologie7, 342–379 (2005).
   Google Scholar
• Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol.23, 619–629 (2005).
   PubMed Web of Science ®Google Scholar
• Gakwaya A, Galukande M, Luwaga A et al. Breast cancer guidelines for Uganda (2nd Edition 2008). Afr. Health Sci.8, 126–132 (2008).
   PubMed Web of Science ®Google Scholar
• National Breast Cancer Centre Hormonal Therapies Guideline Working Group. Recommendations for aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer. Presented at: National Breast Cancer Center. Camperdown, Australia (2006).
   Google Scholar
• Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol.14, 2738–2746 (1996).
   PubMed Web of Science ®Google Scholar
• Mansell J, Monypenny IJ, Skene AI et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res. Treat.117, 91–98 (2009).
   PubMed Web of Science ®Google Scholar
• Kryj M, Maciejewski B, Withers HR, Taylor JM. Incidence and kinetics of distant metastases in patients with operable breast cancer. Neoplasma44, 3–11 (1997).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ; 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann. Oncol.18, 1133–1144 (2007).
   PubMed Web of Science ®Google Scholar
• Cazzaniga ME, Mustacchi G, Pronzato P, De Matteis A, Di Costanzo F, Floriani I; NORA Study Group. Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study. Ann. Oncol.18, 1976–1980 (2007).
   PubMed Web of Science ®Google Scholar
• Jackisch C, Untch M, Dimitrios C et al.; on behalf of the Organgruppe Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie. Adherence to treatment guidelines in breast cancer care – retrospective analysis of the Organgruppe Mamma der Arbeitsgemeinschaft Gynakologische Onkologie. Breast Care3, 87–92 (2008).
   PubMed Web of Science ®Google Scholar
• Latosinsky S, Fradette K, Lix L, Hildebrand K, Turner D. Canadian breast cancer guidelines: have they made a difference? CMAJ176, 771–776 (2007).
   PubMed Web of Science ®Google Scholar
• Short L, Fisher M, Wahl P, White S, Rodriguez N, Kelly M. Patterns of therapy and adherence to established treatment guidelines in Caucasian versus African–American new-episode breast cancer patients. Breast Cancer Res. Treat.106(Suppl. 1), S142–S143 (2007).
   Google Scholar
• Song X, Nicholas G, Dent S, Verma S. Adjuvant hormonal therapy choice in women with early stage breast cancer. Breast Cancer Res. Treat.106(Suppl. 1), S120 (2007).
   Google Scholar
• Jackisch C, Verma S. A global perspective on the use of aromatase inhibitors in early-stage breast cancer. Cancer Res.69(Suppl. 2), 148s (2009) (Abstract 1144).
   Google Scholar
• Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J. Clin. Oncol.20, 3317–3327 (2002).
   PubMed Web of Science ®Google Scholar
• Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J. Clin. Oncol.21, 2597–2599 (2003).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J. Clin. Oncol.19, 3817–3827 (2001).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol.21, 3357–3365 (2003).
   PubMed Web of Science ®Google Scholar
• Baum M, Budzar AU, Cuzick J et al.; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet359, 2131–2139 (2002).
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med.349, 1793–1802 (2003).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ et al.; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med.350, 1081–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J. Clin. Oncol.23, 5138–5147 (2005).
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst.97, 1262–1271 (2005).
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M et al.; ATAC Trialists’ Group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet365, 60–62 (2005).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M et al.; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet366, 455–462 (2005).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ; panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol.16, 1569–1583 (2005).
   PubMed Web of Science ®Google Scholar
• Thürlimann B, Keshaviah A, Coates AS et al.; Breast International Group (BIG) 1–98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med.353, 2747–2757 (2005).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365, 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Coates AS, Keshaviah A, Thürlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J. Clin. Oncol.25, 486–492 (2007).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al.; BIG 1–98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med.361, 766–776 (2009).
   PubMed Web of Science ®Google Scholar
• Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am. J. Surg.192, 496–498 (2006).
   PubMed Web of Science ®Google Scholar
• Regan MM, Colleoni M, Giobbie-Hurder A et al. Adjusting for selective crossover in analyses of letrozole (let) versus tamoxifen (tam) in the BIG 1–98 trial. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December 2009.
   Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF et al.; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet369, 559–570 (2007).
   PubMed Web of Science ®Google Scholar
• Pestalozzi B, Castiglione M; ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.19(Suppl. 2), ii7–ii10 (2008).
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M, Yap YS et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J. Clin. Oncol.24, 2444–2447 (2008).
   Web of Science ®Google Scholar
• Crivellari D, Sun Z, Coates AS et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1–98 trial. J. Clin. Oncol.26, 1972–1979 (2008).
   PubMed Web of Science ®Google Scholar
• Muss HB, Tu D, Ingle JN et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J. Clin. Oncol.26, 1956–1964 (2008).
   PubMed Web of Science ®Google Scholar
• Rea D, Hasenburg A, Seynaeve C et al. Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, Phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December 2009.
   Google Scholar
• Mincey BA, Duh MS, Thomas SK et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin. Breast Cancer7, 127–132 (2006).
   PubMed Web of Science ®Google Scholar
• Thürlimann B; for the BIG 1–98 Collaborative & International Breast Cancer Study Groups. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer: update of the BIG 1–98 Primary Core Analysis (PCA). Presented at: Primary Therapy of Early Breast Cancer 2009, 11th International Conference. St Gallen, Switzerland, 11–14 March 2009.
   Google Scholar
• De Boer R, Burris H, Monnier A et al.; on behalf of the H2H trial steering committee. The Head to Head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J. Clin. Oncol.24(18S), 582s (2006) (Abstract 10672).
   Google Scholar
• Monnier A. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. Expert Rev. Anticancer Ther.6(10), 1355–1359 (2006).
   PubMed Web of Science ®Google Scholar
• Jonat W, Mundhenke C. The FACE trial: letrozole or anastrozole as initial adjuvant therapy? Cancer Invest.25, 14–18 (2007).
   PubMed Web of Science ®Google Scholar
• Ingle JN, Tu D, Pater JL et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res. Treat.99, 295–300 (2006).
   PubMed Web of Science ®Google Scholar
• Ingle JN, Tu D, Pater JL et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann. Oncol.19, 877–882 (2008).
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Lembersky B, Jeong JH et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin. Breast Cancer7, 416–421 (2006).
   PubMed Web of Science ®Google Scholar